Thermo Fisher Scientific Inc. $TMO Shares Acquired by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,101 shares of the medical research company’s stock after purchasing an additional 329 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in Thermo Fisher Scientific were worth $852,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Flossbach Von Storch SE increased its holdings in shares of Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after acquiring an additional 1,314,182 shares during the last quarter. Nuveen LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at approximately $532,360,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Thermo Fisher Scientific by 29.5% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after purchasing an additional 514,399 shares in the last quarter. EdgePoint Investment Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $172,139,000. Finally, Lindsell Train Ltd grew its position in shares of Thermo Fisher Scientific by 68.0% in the 2nd quarter. Lindsell Train Ltd now owns 854,612 shares of the medical research company’s stock valued at $346,511,000 after buying an additional 345,822 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $567.49 on Tuesday. The business has a 50 day simple moving average of $529.51 and a 200-day simple moving average of $469.36. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock has a market capitalization of $213.21 billion, a PE ratio of 32.78, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the previous year, the company posted $5.28 EPS. Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has approved a share repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 4,638 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $594.42, for a total value of $2,756,919.96. Following the completion of the sale, the chief operating officer owned 23,480 shares of the company’s stock, valued at approximately $13,956,981.60. This trade represents a 16.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the transaction, the vice president directly owned 14,145 shares in the company, valued at approximately $8,085,564.90. This trade represents a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 52,140 shares of company stock worth $29,104,464 in the last three months. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TMO has been the subject of a number of research reports. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a research report on Tuesday, October 28th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.